| Jul 15 |
Institutional investors are Silence Therapeutics plc's (NASDAQ:SLN) biggest bettors and were rewarded after last week's US$76m market cap gain
|
| Jul 12 |
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
|
| Jun 24 |
Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma
|
| Jun 24 |
Silence Therapeutics achieves $2M research milestone payment from Hansoh collaboration
|
| Jun 24 |
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
|
| Jun 21 |
Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results
|
| Jun 20 |
Silence releases promising phase 2 results of zerlasiran to lower lipoprotein
|
| Jun 20 |
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
|
| May 30 |
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
|
| May 21 |
Silence Therapeutics (NASDAQ:SLN) Is In A Good Position To Deliver On Growth Plans
|
